Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVEST trial of early oral step-down versus continued intravenous antibiotics for uncomplicated Gram-negative bacteraemia
2024-517308-13-00Phase 4Completed
- Sponsor
- Tan Tock Seng Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 4, randomised, open-label trial of levofloxacin and trimethoprim + sulfamethoxazole in gram-negative bacteremia (2 arms), sponsored by Tan Tock Seng Hospital. Primary endpoint: All-cause mortality at day 30. Started Dec 2025; status: completed.
02
Drugs
levofloxacintrimethoprim + sulfamethoxazole
03
Conditions
gram-negative bacteremia
Beyond the preview
Go deeper on 2024-517308-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517308-13-00.